Vanda Pharmaceuticals (VNDA) Current Deferred Revenue (2010 - 2014)

Vanda Pharmaceuticals has reported Current Deferred Revenue for 5 years, with the latest figure at $247000.0 in Q4 2014.

• Quarterly Current Deferred Revenue fell 99.73% year-over-year to $247000.0 in Q4 2014, while the trailing twelve-month figure through Dec 2014 was $247000.0 (down 99.73% YoY) and the FY2014 annual result came in at $247000.0, down 99.73% from the prior year.
• Current Deferred Revenue declined to $247000.0 in Q4 2014 per VNDA's latest filing, from $31.2 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $170.6 million in Q4 2010 and troughed at $234000.0 in Q2 2014.
• A 5-year average of $87.1 million and a median of $100.4 million in 2013 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2012 and 2014: Current Deferred Revenue soared 387.4% in 2012, then plunged 99.77% in 2014.
• Over 5 years, Current Deferred Revenue stood at $170.6 million in 2010, then fell by 15.7% to $143.9 million in 2011, then slipped by 18.62% to $117.1 million in 2012, then declined by 22.88% to $90.3 million in 2013, then slumped by 99.73% to $247000.0 in 2014.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $247000.0, $31.2 million, and $234000.0 for Q4 2014, Q3 2014, and Q2 2014 respectively.